Navrogen is at the forefront of Humoral Immuno-Oncology (HIO), focusing on developing innovative therapeutic agents that counteract the immunosuppressive factors produced by tumors. Their approach involves identifying and targeting these HIO factors, which can diminish the effectiveness of existing therapies like rituximab and Herceptin. The company employs proprietary technologies, including their Block-Removed Immunoglobulin Technology (BRITE) and HIO screening platforms, to create a pipeline of therapeutic agents that are resistant to these immunosuppressive effects. Notable products in their pipeline include NAV-001, an antibody-drug conjugate targeting mesothelin, and NAV-006, a next-generation version of rituximab designed to be more effective against HIO-1-positive Non-Hodgkin’s Lymphoma.

Navrogen's research emphasizes the importance of understanding the tumor microenvironment and its role in suppressing humoral immunity. Their unique pipeline includes various agents such as NAV-201, which activates natural killer (NK) cells to combat tumor cells, and NAV-004, an immunotoxin targeting regulatory T cells to restore immune function. By leveraging their extensive experience in biotechnology and a deep understanding of cancer biology, Navrogen aims to translate clinical knowledge into effective treatments that can improve patient outcomes in cancers characterized by HIO suppression.

United States

Navrogen Inc. is a biopharmaceutical company focused on the targeted treatment of cancer. Navrogen is currently working on enhancing the immune system to fight cancer by removing the effect of factors produced or induced by tumor cells which inhibit the cancer-fighting humoral immune system.

Navrogen

Company Details